Targets for immunochemotherapy in leishmaniasis

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 261-264

  Mukhopadhyay, Debanjan ^a   Saha, Piu ^a   Chatterjee, Mitali ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

immunomodulation; leishmaniasis; MAPK; NF B; PI3K; PKC; Toll like receptor

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; AMPHOTERICIN B; ANTIMONY GLUCONATE; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; FLUCONAZOLE; GAMMA INTERFERON; GLYCYRRHETINIC ACID; IMIQUIMOD; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 12; INTERLEUKIN 2; KETOCONAZOLE; KUTKIN; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE; PAROMOMYCIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA;

CELL PHAGOCYTOSIS; CELLULAR IMMUNITY; CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LEISHMANIASIS; NONHUMAN; PARASITE LOAD; PROTEIN EXPRESSION; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEISHMANIASIS; MACROPHAGES; MICE; SIGNAL TRANSDUCTION;

EID: 84858168877     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.17     Document Type: Review

References (34)

1. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19(11), 502-508 (2003). (Pubitemid 37329659)
2. Dalton JE, Kaye PM. Immunomodulators: use in combined therapy against leishmaniasis. Expert Rev. Anti Infect. Ther. 8(7), 739-742 (2010).
3. den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Clin. Microbiol. Infect. 17(10), 1471-1477 (2011).
4. Antinori S, Schifanella L, Corbellino M. Leishmaniasis: new insights from an old and neglected disease. Eur. J. Clin. Microbiol. Infect. Dis. 31(2), 109-118 (2012).
5. Matlashewski G, Arana B, Kroeger A et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect. Dis. 11(4), 322-325 (2011).
6. Van Assche T, Deschacht M, da Luz RA, Maes L, Cos P. Leishmania- macrophage interactions: insights into the redox biology. Free Radic. Biol. Med. 51(2), 337-351 (2011).
7. Dey R, Khan S, Pahari S, Srivastava N, Jadhav M, Saha B. Functional paradox in host-pathogen interaction dictates the fate of parasites. Future Microbiol. 2(4), 425-437 (2007). (Pubitemid 47365027)
8. Bhardwaj S, Srivastava N, Sudan R, Saha B. Leishmania interferes with host cell signaling to devise a survival strategy. J. Biomed. Biotechnol. 109189 (2010) (2010).
9. Laskay T, van Zandbergen G, Solbach W. Neutrophil granulocytes as host cells and transport vehicles for intracellular pathogens: apoptosis as infection-promoting factor. Immunobiology 213(3-4), 183-191 (2008).
10. Saha P, Mukhopadhyay D, Chatterjee M. Immunomodulation by chemotherapeutic agents against leishmaniasis. Int. Immunopharmacol. 11(11), 1668-1679 (2011).
11. Kulshrestha A, Singh R, Kumar D, Negi NS, Salotra P. Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine. Antimicrob. Agents Chemother. 55(6), 2916-2921 (2011).
12. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179(6), 1485-1494 (1999). (Pubitemid 29246599)
13. Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3(7), e491 (2009).
14. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J. Infect. Dis. 171(4), 992-996 (1995).
15. Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70(11), 6284-6293 (2002). (Pubitemid 35192720)
16. Murray HW, Brooks EB, DeVecchio JL, Heinzel FP. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47(8), 2513-2517 (2003). (Pubitemid 36919453)
17. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J. Immunol. 170(11), 5625-5629 (2003). (Pubitemid 36617853)
18. Almeida RP, Brito J, Machado PL et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am. J. Trop. Med. Hyg. 73(1), 79-81 (2005). (Pubitemid 41278752)
19. El-On J. Current status and perspectives of the immunotherapy of leishmaniasis. Isr. Med. Assoc. J. 11(10), 623-628 (2009).
20. Banerjee A, De M, Ali N. Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrob. Agents Chemother. 55(4), 1661-1670 (2011).
21. Sane SA, Shakya N, Gupta S. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. Exp. Parasitol. 127(2), 376-381 (2011).
22. Shakya N, Sane SA, Gupta S. Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator -picroliv. Parasitol. Res. 108(4), 793-800 (2011).
23. Shakya N, Sane SA, Vishwakarma P, Bajpai P, Gupta S. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator -picroliv. Acta. Trop. 119(2-3), 188-193 (2011).
24. Sane SA, Shakya N, Haq W, Gupta S. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. J. Antimicrob. Chemother. 65(7), 1448-1454 (2010).
25. Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, Chatterjee M. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J. Infect. Dis. 204(9), 1427-1436 (2011).
26. Ansari NA, Ramesh V, Salotra P. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 102(11), 1160-1162 (2008).
27. Awasthi A, Mathur R, Khan A et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med. 197(8), 1037-1043 (2003). (Pubitemid 36523201)
28. Raman VS, Bhatia A, Picone A et al. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol. 185(3), 1701-1710 (2010).
29. Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol. 182(11), 7146-7154 (2009).
30. Yamauchi S, Ito H, Miyajima A. IkappaBeta, a nuclear IkappaB protein, positively regulates the NF-kappaB-mediated expression of proinflammatory cytokines. Proc. Natl Acad. Sci. USA 107(26), 11924-11929 (2010).
31. Ukil A, Biswas A, Das T, Das PK. 18 Beta-glycyrrhetinic acid triggers curative Th1 response and nitric oxide up-regulation in experimental visceral leishmaniasis associated with the activation of NF-kappa B. J. Immunol. 175(2), 1161-1169 (2005). (Pubitemid 41095003)
32. Mukherjee AK, Gupta G, Bhattacharjee S et al. Amphotericin B regulates the host immune response in visceral leishmaniasis: reciprocal regulation of protein kinase C isoforms. J. Infect. 61(2), 173-184 (2010).
33. Cummings HE, Barbi J, Reville P et al. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc. Natl Acad. Sci. USA 109(4), 1251-1256 (2012).
34. Sen R, Chatterjee M. Plant derived therapeutics for the treatment of leishmaniasis. Phytomedicine 18(12), 1056-1069 (2011).